Azilsartan Decreases Renal and Cardiovascular Injury in the Spontaneously Hypertensive Obese Rat

被引：25

作者：

Khan, Md. Abdul Hye ^{[1
]}

Neckar, Jan ^{[1
,3
]}

Cummens, Breana ^{[1
]}

Wahl, Geneva M. ^{[1
]}

Imig, John D. ^{[1
,2
]}

机构：

[1] Med Coll Wisconsin, Dept Pharmacol & Toxicol, Milwaukee, WI 53226 USA

[2] Med Coll Wisconsin, Ctr Cardiovasc, Milwaukee, WI 53226 USA

[3] Acad Sci Czech Republic, Inst Physiol, Prague, Czech Republic

来源：

CARDIOVASCULAR DRUGS AND THERAPY | 2014年 / 28卷 / 04期

关键词：

Angiotensin receptor blocker; Kidney; Metabolic syndrome; Heart; II RECEPTOR BLOCKER; METABOLIC SYNDROME; ENDOTHELIAL DYSFUNCTION; MYOCARDIAL-INFARCTION; INSULIN-RESISTANCE; ADIPOSE-TISSUE; MODEL; INHIBITION; MEDOXOMIL; PRESSURE;

D O I：

10.1007/s10557-014-6530-0

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Angiotensin II type 1 receptor blockers (ARBs) are widely used in treating hypertension. In the present study, we tested the hypothesis that a novel ARB, azilsartan medoxomil (AZL-M) will prevent renal and cardiovascular injury in the spontaneously hypertensive obese rat (SHROB), a model of cardiometabolic syndrome. Male SHROB were treated with vehicle or AZL-M orally for 56 days. Vehicle treated normotensive Wistar-Kyoto (WKY) rats served as controls. The effects of AZL-M on kidney injury, vascular endothelial and heart functions, lipid profile, and glucose tolerance were assessed. AZL-M demonstrated anti-hypertensive effects along with markedly improved vascular endothelial function in SHROB. In these rats, AZL-M demonstrates strong kidney protective effects with lower albuminuria and nephrinuria along with reduced tubular cast formation and glomerular injury. AZL-M treatment also improved left ventricular heart function, attenuated development of left ventricular hypertrophy, and reduced cardiac fibrosis in SHROB. Overall, these findings demonstrate kidney and heart protective effects of AZL-M in SHROB, and these effects were associated with its ability to lower blood pressure and improve endothelial function.

引用

页码：313 / 322

页数：10

共 46 条

[1] Azilsartan Medoxomil: A New Angiotensin II Receptor Antagonist for Treatment of Hypertension [J].

Baker, William L. ;

White, William B. .

ANNALS OF PHARMACOTHERAPY, 2011, 45 (12) :1506-1515

[2] The Comparative Effects of Azilsartan Medoxomil and Olmesartan on Ambulatory and Clinic Blood Pressure [J].

Bakris, George L. ;

Sica, Domenic ;

Weber, Michael ;

White, William B. ;

Roberts, Andrew ;

Perez, Alfonso ;

Cao, Charlie ;

Kupfer, Stuart .

JOURNAL OF CLINICAL HYPERTENSION, 2011, 13 (02) :81-88

[3] The Efficacy and Tolerability of Azilsartan in Mice With Left Ventricular Pressure Overload or Acute Myocardial Infarction [J].

Baumann, Patricia Quinn ;

Zaman, Tarikuz ;

McElroy-Yaggy, Keara ;

Sobel, Burton E. .

JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2013, 61 (05) :437-443

[4] Valsartan Protects Pancreatic Islets and Adipose Tissue From the Inflammatory and Metabolic Consequences of a High-Fat Diet in Mice [J].

Cole, Banumathi K. ;

Keller, Susanna R. ;

Wu, Runpei ;

Carter, Jeffrey D. ;

Nadler, Jerry L. ;

Nunemaker, Craig S. .

HYPERTENSION, 2010, 55 (03) :715-U59

[5] The Effect of Chronic Candesartan Therapy on the Metabolic Profile and Renal Tissue Cytokine Levels in the Obese Zucker Rat [J].

Ecelbarger, Carolyn M. ;

Rash, Arjun ;

Sinha, Rajesh K. ;

Tiwari, Swasti .

MEDIATORS OF INFLAMMATION, 2010, 2010

[6] Obesity is the major contributor to vascular dysfunction and inflammation in high-fat diet hypertensive rats [J].

Elmarakby, Ahmed A. ;

Imig, John D. .

CLINICAL SCIENCE, 2010, 118 (3-4) :291-301

[7] Molecular pathology in the obese spontaneous hypertensive Koletsky rat: A model of Syndrome X [J].

Ernsberger, P ;

Koletsky, RJ ;

Friedman, JE .

THE METABOLIC SYNDROME X: CONVERGENCE OF INSULIN RESISTANCE, GLUCOSE INTOLERANCE, HYPERTENSION, OBESITY, AND DYSLIPIDEMIAS-SEARCHING FOR THE UNDERLYING DEFECTS, 1999, 892 :272-288

[8] Therapeutic actions of allylmercaptocaptopril and captopril in a rat model of metabolic syndrome [J].

Ernsberger, Paul ;

Johnson, Janean L. ;

Rosenthal, Talma ;

Mirelman, David ;

Koletsky, Richard J. .

AMERICAN JOURNAL OF HYPERTENSION, 2007, 20 (08) :866-874

[9] Peroxisome proliferator-activated receptor-alpha (PPARα): At the crossroads of obesity, diabetes and cardiovascular disease [J].

Fruchart, Jean-Charles .

ATHEROSCLEROSIS, 2009, 205 (01) :1-8

[10] Early experimental obesity is associated with coronary endothelial dysfunction and oxidative stress [J].

Galili, Offer ;

Versari, Daniele ;

Sattler, Katherine J. ;

Olson, Monica L. ;

Mannheim, Dallit ;

McConnell, Joseph P. ;

Chade, Alejandro R. ;

Lerman, Lilach O. ;

Lerman, Amir .

AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, 2007, 292 (02) :H904-H911

← 1 2 3 4 5 →